Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene

Gene Therapy volume 23, pages 839–845 (2016)Cite this article

Subjects

Abstract

The immune effect and safety evaluation of rAAV (recombinant adeno-associated virus)-containing Bcsg1 (breast cancer-specific gene 1) (rAAV/Bcsg1)-transfected DC (dendritic cell) (rAAV/Bcsg1-DC) vaccine in immunotherapy for (BCSG1) (+) BC was assessed. Immune effect of cytotoxic T lymphocytes (CTLs) on Bcsg1 (+) BC cells, and rAAV gene residuals in mature CTL cells and culture medium were determined. Nude mouse xenograft tumor model was established to assess the inhibition effects of DC-activated CTLs on tumor growth. DC cell surface markers were highly expressed in rAAV/Bcsg1 group and lysate-DC group, and rAAV/Bcsg1-DC-CTL showed stronger cytotoxic activity targeting Bcsg1 (+) BC cells. The rAAV/Bcsg1-DC vaccine-treated groups showed lower mean tumor weight, higher tumor inhibition rates and slower tumor growth. rAAV/Bcsg1-DC can induce highly efficient CTL-targeting Bcsg1 antigen without rAAV gene residuals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Fan L, Strasser-Weippl K, Li JJ, Louis J St, Finkelstein DM, Yu KD et al. Breast cancer in China. Lancet Oncol 2014; 15: e279–e289.

    Article  Google Scholar 

  2. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X . Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014; 2: 61.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A . Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 2008; 60: 173–183.

    Article  CAS  Google Scholar 

  4. Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–277.

    Article  CAS  Google Scholar 

  5. Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S et al. Immunity to pathogens taught by specialized human dendritic cell subsets. Front Immunol 2015; 6: 527.

    Article  Google Scholar 

  6. Kajihara M, Takakura K, Ohkusa T, Koido S . The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies. Immunotherapy 2015; 7: 1111–1122.

    Article  CAS  Google Scholar 

  7. Anderson KS . Tumor vaccines for breast cancer. Cancer Invest 2009; 27: 361–368.

    Article  CAS  Google Scholar 

  8. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother 2014; 10: 52–63.

    Article  CAS  Google Scholar 

  9. Koido S, Hara E, Homma S, Fujise K, Gong J, Tajiri H . Dendritic/tumor fusion cell-based vaccination against cancer. Arch Immunol Ther Exp (Warsz) 2007; 55: 281–287.

    Article  CAS  Google Scholar 

  10. Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, Sui Y et al. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007; 105: 277–286.

    Article  CAS  Google Scholar 

  11. Koido S, Tanaka Y, Tajiri H, Gong J . Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 2007; 25: 2610–2619.

    Article  CAS  Google Scholar 

  12. Zhou J, Ma P, Li J, Song W . Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carrying alpha-fetoprotein gene or cancer cell lysate. Mol Med Rep 2015; 11: 3174–3180.

    Article  CAS  Google Scholar 

  13. Zheng L, Weilun Z, Minghong J, Yaxi Z, Shilian L, Yanxin L et al. Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice. BMC Cancer 2012; 12: 153.

    Article  Google Scholar 

  14. He ZH, Lei Z, Zhen Y, Gong W, Huang B, Yuan Y et al. Adeno-associated virus-mediated expression of recombinant CBD-HepII polypeptide of human fibronectin inhibits metastasis of breast cancer. Breast Cancer Res Treat 2014; 143: 33–45.

    Article  CAS  Google Scholar 

  15. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57: 759–764.

    CAS  PubMed  Google Scholar 

  16. Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res 2014; 16: 204.

    Article  Google Scholar 

  17. Ernst B, Anderson KS . Immunotherapy for the treatment of breast cancer. Curr Oncol Rep 2015; 17: 5.

    Article  Google Scholar 

  18. Goel G, Sun W . Cancer immunotherapy in clinical practice – the past, present, and future. Chin J Cancer 2014; 33: 445–457.

    Article  CAS  Google Scholar 

  19. Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S . Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res 2007; 13: 3968–3976.

    Article  CAS  Google Scholar 

  20. Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother 2007; 56: 1615–1624.

    Article  CAS  Google Scholar 

  21. Sallusto F . DCs: a dual bridge to protective immunity. Nat Immunol 2013; 14: 890–891.

    Article  CAS  Google Scholar 

  22. Simon T, Tanguy-Royer S, Royer PJ, Boisgerault N, Frikeche J, Fonteneau JF et al. Human dendritic cells sequentially matured with CD4(+) T cells as a secondary signal favor CTL and long-term T memory cell responses. Biol Res 2012; 45: 33–43.

    Article  Google Scholar 

  23. Batchu RB, Gruzdyn OV, Moreno-Bost AM, Szmania S, Jayandharan G, Srivastava A et al. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine 2014; 32: 938–943.

    Article  CAS  Google Scholar 

  24. Wang XL, Ma B, Jia J, Yuan YH, Yan Y, Di LJ et al. [Dendritic cells infected by recombinant adeno-associated virus with CEA gene to induce antigen-specific CTL response to CD44(+)CD24(-/low) cells from MCF-7 breast cancer cell line]. Beijing Da Xue Xue Bao 2011; 43: 173–178.

    CAS  PubMed  Google Scholar 

  25. Chau J, Moza D, Hossain N, Lee JK, Bienenstock J, Karimi K . Increased production of IFN-gamma by natural killer cells triggered with bone marrow-derived dendritic cells cultured in the presence of retinoic acid. Eur J Pharmacol 2013; 715: 321–327.

    Article  CAS  Google Scholar 

  26. Steel JC, Di Pasquale G, Ramlogan CA, Patel V, Chiorini JA, Morris. JC . Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer. Mol Ther 2013; 21: 680–687.

    Article  CAS  Google Scholar 

  27. Yiang GT, Chou PL, Tsai HF, Chen LA, Chang WJ, Yu YL et al. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. Int J Mol Med 2012; 29: 809–814.

    CAS  PubMed  Google Scholar 

  28. Luo J, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X . Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett 2015; 356: 347–356.

    Article  CAS  Google Scholar 

  29. Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 2012; 14: 80–90.

    Article  CAS  Google Scholar 

  30. Di L, Zhu Y, Jia J, Yu J, Song G, Zhang J et al. Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin Transl Oncol 2012; 14: 675–681.

    Article  CAS  Google Scholar 

  31. Milani A, Sangiolo D, Aglietta M, Valabrega G . Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press) 2014; 6: 159–168.

    CAS  Google Scholar 

  32. Glas J, Seiderer J, Bues S, Stallhofer J, Fries C, Olszak T et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One 2013; 8: e54338.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This project was supported by Natural Science Foundation of Shandong Province (ZR2015HL063) and Medical Science Foundation of Shandong Province (2014WS0300), and we would like to acknowledge the helpful comments received from our reviewers.

Author contributions

S-FC and WZ wrote the main manuscript text, W-HW and C-HZ collected the data, JD and Y-XZ prepared all the tables, and L-LZ analyzed the data. All authors reviewed the manuscript.

Author information

Author notes

  1. W-H Wang and C-H Zhou: Co-first authors.

Authors and Affiliations

  1. Central Laboratory, Liaocheng People’s Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, PRC

    W-H Wang, C-H Zhou, J Ding, Y-X Zhang, L-L Zheng & S-F Chen

  2. Surgery of Mammary Gland and Thyroid, Liaocheng People’s Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, PRC

    W Zhang

Authors
  1. W-H Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C-H Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-X Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L-L Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S-F Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to S-F Chen or W Zhang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, WH., Zhou, CH., Ding, J. et al. Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene. Gene Ther 23, 839–845 (2016). https://doi.org/10.1038/gt.2016.63

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2016.63

This article is cited by

Search

Advanced search

Quick links